We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Analytical Performance of Novel Glycated Albumin Assay Evaluated

By LabMedica International staff writers
Posted on 26 May 2022
Print article
Image: The Lucica Glycated Albumin-L assay is a new diagnostic test for measuring GA. The test is based on an enzymatic method that uses liquid reagents requiring no preparation (Photo courtesy of Asahi Kasei Pharma Corporation)
Image: The Lucica Glycated Albumin-L assay is a new diagnostic test for measuring GA. The test is based on an enzymatic method that uses liquid reagents requiring no preparation (Photo courtesy of Asahi Kasei Pharma Corporation)

Diabetes is a complex, chronic illness requiring continuous medical care with multifactorial risk-reduction strategies beyond glycemic control. Hemoglobin A1c (HbA1c) reflects the concentration of mean plasma glucose (MPG) over the last 2–3 months and has been the gold standard for monitoring glycemic control of diabetic patients in clinical practice.

Glycated Albumin (GA) is an intermediate-term glycemic indicator that reflects the glycemic control status for the previous 2–3 weeks due to the albumin half-life. GA is an important HbA1c substitute for assaying samples with hemoglobin variants and abnormal hemoglobin metabolism because it is unrelated to this pathway. More importantly, GA changes quicker than HbA1c and might be a useful marker for detecting short-term changes of glycemic control during treatment.

Scientists specializing in diagnostics from the Asahi Kasei Pharma Corporation (Yurakucho, Japan) evaluated the performance of the company’s Lucica Glycated Albumin-L, a new GA assay that is traceable to standard reference materials and determined the reference range in healthy subjects without diabetes. They confirmed the reference range of GA in a healthy, non-diabetic population in the USA following CLSI Guideline EP28-A3C. A single-visit 2-site study in the United States was designed. The observed value of GA in subjects with diabetes was confirmed following the same CLSI Guideline. One hundred and fifty subjects with diabetes (≥18 years of age) from eight different sites were tested. The team compared the standardized new GA assay with the old assay and developed the GA reference range in healthy subjects without diabetes in the USA.

The investigators reported that the coefficient of variation (CV) of overall repeatability, within-laboratory precision, and overall reproducibility values of GA values were not more than 2.6%, 3.3%, and 1.6%, respectively, among laboratories. The GA values showed good linearity from 173 to 979 mmol/mol (9.4%–54.9%) across the assay range. The GA reference range in 262 healthy subjects was between 183 and 259 mmol/mol (9.9%–14.2%), while that of subjects with diabetes was 217–585 mmol/mol (11.8–32.6%). The reagent was stable for two months on the bench at room temperature. The limits of blank, detection, and qualification were 6.9, 7.9, and 9.7 μmol/L for GA concentration, and 3.8, 7.0, and 21.8 μmol/L for albumin concentration, respectively. Hemoglobin slightly affected the assay, while other classical interfering substances had no significant impact.

The authors conclude that the Lucica Glycated Albumin-L assay is traceable to standard reference materials, shows excellent performance, and could be a useful diagnostic test for the intermediate-term monitoring of glycemic control in patients with diabetes. The study was published on May 20, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
Asahi Kasei Pharma Corporation 

Automated ELISA-IFA-BLOT Processor AP 22
New
Gold Supplier
pHOx Analyzer
BioProfile pHOx Analyzer
New
Nucleic Acid Extraction System
Natch 48
New
ELISA & CLIA Analyzer
Autoplex Gen2

Print article

Channels

Molecular Diagnostics

view channel
Image: A new machine rapidly and robustly separates cancer cells from blood samples (Photo courtesy of DGIST)

Centrifugal System for Separating Circulating Tumor Cells from Blood Samples to Improve Cancer Diagnosis

Circulating tumor cells are cells that break off from cancers and are released into the blood stream. They can go on to form the seeds for new tumor formation in other parts of the body, known as metastases.... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.